Latest news

Adalvo is pleased to announce the successful EU DCP Submission for Ivermectin 10mg/g topical cream. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave...

We are thrilled to announce the successful completion of the Pivotal BE Study for Semaglutide 1.34mg/ml pre-filled pen, a product developed in collaboration with one of our strategic partners.  This...

Adalvo has achieved another milestone by successfully completing its Pivotal BE program for the 0.15mg/0.02mg strength of its Desogestrel+Ethinylestradiol film-coated tablets, following the recent news of the completion of the...

We are pleased to announce that we have now completed our Pivotal BE program for Desogestrel+Ethinylestradiol film-coated tablets 0.15mg/0.03mg. This product has been developed in collaboration with one of our...

We are pleased to announce that we have now completed our Pivotal BE program for Levonorgestrel+Ethinylestradiol film-coated tablets 0.15mg/0.03mg. This product has been developed in collaboration with one of our strategic partners....

Adalvo is thrilled to announce that we have successfully completed our Pilot BE program for Empagliflozin+Metformin 12.5mg/1000mg film-coated tablets. This product has been developed in collaboration with one of our...

Adalvo is pleased to announce the successful EU dossier submission for Dalbavancin powder. This achievement further strengthens our infectiology product pipeline and positions Adalvo amongst the few players able to...

We are pleased to announce our successful Pivotal BE results for Mirabegron prolonged release tablets. We will proceed with DCP submission, which is scheduled for June 2023

Adalvo is pleased to announce that we have entered into a partnership with ADVANZ PHARMA, signing an exclusive licensing and supply agreement for a complex, specialty injectable generic for multiple...

We are pleased to announce that we have now completed our Pivotal BE program for Dapagliflozin 10mg film-coated tablets.

Nuvyor (lenalidomide) is the first similar announced in the Brazilian market and marks the strengthening of pharmaceuticals in the area of oncologic hematology. Adalvo is pleased to announce that...

Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine hard capsules, which has been developed in close collaboration with one of our strategic partners.

Adalvo is delighted to announce the completion of second wave MA approvals for Solifenacin + Tamsulosin, in various EU markets, with several successful DCP approvals.

Adalvo is pleased to announce that we have extended our strategic partnership with Bioventure, the subsidiary of Healthcare Division of Yas Holding, signing a licensing deal for four molecules, within...

Adalvo is pleased to announce the successful EU dossier submission for Apremilast Film-Coated tablets on day-1, after expiry of data exclusivity.

Adalvo expects to file 30 DCPs within 2023. Here is a glimpse on our exciting DCP filing plans for 2023.

Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes

Adalvo is pleased to announce that we have extended our strategic partnership with Zentiva, signing a licensing deal for three molecules, within Europe.

Adalvo and Frontier Biopharma/Zdravlje (“Frontier”) are pleased to announce their collaboration in several therapeutic areas for the markets of Central and Eastern Europe and the Balkans. Over the next months...

Adalvo is delighted to announce the successful DCP closure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With this achievement, we believe we will be amongst the first companies to...

Adalvo is pleased to announce that we have successfully launched Vinorelbine soft gel capsules in Israel.